SCOR (SCR) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
2 Nov, 2025Executive summary
Net income reached EUR 217 million in Q3 2025, with adjusted net income at EUR 211 million and annualized ROE of 21.5%–22.1%, reflecting strong profitability and operational performance across all segments.
Economic Value increased by 12.7% at constant FX versus YE 2024, reaching EUR 8.5 billion, driven by P&C and investment performance.
Group solvency ratio stood at 210% as of September 30, 2025, at the upper end of the optimal range, supporting financial stability.
Focus remains on underwriting discipline, capital efficiency, and risk-adjusted returns amid a more competitive market.
Teams are encouraged to seek profitable opportunities without explicit growth targets, prioritizing long-term value creation.
Financial highlights
Q3 2025 net income was EUR 217 million (EUR 211 million adjusted), with a 21.5% ROE; 9M 2025 net income was EUR 642 million and 19.5% ROE.
Q3 2025 insurance revenue was EUR 3.7 billion, down 5.8% year-over-year; gross written premiums were EUR 4.6 billion, down 8.3%.
P&C combined ratio improved to 80.9% in Q3 2025 (down 7.5 pts year-over-year), well below the Forward 2026 assumption of <87%.
Life and health insurance service result of EUR 98 million in Q3 2025; year-to-date ISR at EUR 334 million, on track for EUR 400 million annual target.
Investment income yield at 3.5% for Q3 2025, with economic value per share at EUR 48.12 and return on invested assets at 3.3%.
Outlook and guidance
Full-year economic value growth expected to exceed Forward 2026 guidance of 9%, with annualized ROE above 12% and P&C combined ratio below 87%.
Life and health new business CSM/ESM on track for EUR 0.4 billion annual assumption, supported by solid CSM amortization.
Revenue growth targets are now outcomes, not objectives; focus is on market conditions and price adequacy.
Management expects to continue leveraging its Tier 1 franchise and execute the Forward 2026 plan with disciplined underwriting and buffer building.
Latest events from SCOR
- FY net income up to EUR 851M, ROE above 19%, dividend EUR 1.9/share, solvency 215%.SCR
Q4 20254 Mar 2026 - Q2 2024 net loss driven by L&H review, but P&C and solvency remain strong.SCR
Q2 202410 Feb 2026 - H1 2025 net income EUR 425m, ROE 20.3%, P&C combined ratio 82.5%, solvency 210%.SCR
Q2 202510 Feb 2026 - January 2026 renewals drove 14.8% EGPI growth and improved underwriting in a competitive market.SCR
Investor update4 Feb 2026 - Strong P&C and investment results offset by L&H review, solvency robust at 203%.SCR
Q3 202414 Jan 2026 - Forward 2026 targets 9% value growth, >12% ROE, higher-margin L&H, and robust solvency.SCR
Investor Day 202411 Jan 2026 - 9.6% EGPI growth driven by Specialty and Alternative Solutions, with stable profitability.SCR
Investor Update9 Jan 2026 - Q4 2024 net income EUR 233m, adjusted FY net income EUR 728m, solvency at 210%, dividend EUR 1.8.SCR
Q4 202413 Dec 2025 - Q1 2025 net income hit EUR 200m, with robust solvency and strong segment performance.SCR
Q1 202518 Nov 2025